Evaluation of Doses to Pelvic Lymph Nodes in 3D-planned High-Dose Rate Interstitial Brachytherapy for Carcinoma of Uterine Cervix

Interstitial brachytherapy (ISBT) is indicated in the definitive management of intact cervical carcinoma (IN-CC) if intracavitary brachytherapy (ICRT) yields unsatisfactory dosimetry or is technically not feasible. ISBT is also the brachytherapy of choice in patients of vault carcinoma (VA-C), where it provides excellent coverage with better sparing of the organs at risk. While, studies have assessed doses to pelvic lymph nodes in ICRT, the same has not been reported in ISBT. The present study evaluates the doses to pelvic lymph node groups in patients of carcinoma cervix treated with ISBT.

Source: Brachytherapy - June 23, 2018 Category: Cancer & Oncology Authors: Ajeet Kumar Gandhi, Madhup Rastogi, Satyajeet Rath, Praffulla Chandra Rai, Sambit Swarup Nanda, S. Farzana, Anoop Kumar Srivastava, Surendra Prasad Mishra, Daya Nand Sharma Source Type: research